by Raynovich Rod | May 15, 2022 | 2021 Rayno Biopharmaceuticals Portfolio
May 22-Update-2 A crazy volatile week but our focus large cap biopharmas are still up YTD. And our spec trades in biotech look better because they are less susceptible to macro news and trade on technicals more so than fundamentals. Here is a snapshot of what...
by Raynovich Rod | May 8, 2022 | 2021 Rayno Biopharmaceuticals Portfolio, Macro
Update-2 …5/13 Many analysts see today’s sharp upside action as an oversold rally from 2022 lows.The highest risk stocks soared along with large cap tech stocks. NASDAQ was up 3.75%,S&P up 2.3%, DOW up 1.42%. To some extent this shifted action away...
by Raynovich Rod | Apr 28, 2022 | 2021 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update -5 …5/6 A wild volatile week catalyzed by FED policy statements. We won’t go into the debate over FED communications about rate hikes and just say that rising rates are a headwind for equities and curb speculation. With higher rates small cap growth...
by Raynovich Rod | Apr 17, 2022 | 2021 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Healthcare stocks
4/26 The constellation of bad news is overwhelming the market: China lock-down, War in Ukraine, commodity prices and WTI up and a horrible tape. MSFT earnings should help us tomorrow but we are in a bear mindset. IBB down 3.86% to $119.39 a 52 week low and the XBI...
by Raynovich Rod | Apr 11, 2022 | 2021 Rayno Biopharmaceuticals Portfolio, Healthcare stocks
Update-2 4/13 11;36 AM EDT….GSK buys Sierra Oncology (SRRA) for $1.9B https://www.bizjournals.com/sanjose/news/2022/04/13/glaxosmithkline-to-buy-sierra-oncology-for-19b.html?ana=yahoo XBI up 2.48% to $89 handle, ARKG up 2.35%. Large caps lag except REGN up. ABBV...
by Raynovich Rod | Apr 4, 2022 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio
Update-2 …4/6 In volatile end of day trading with Tech stocks and the NASDAQ hit hard down 2.2%, healthcare stocks were winners with the XLV up 1.5%. Other sector winners were staples, energy, real estate and utilities. As one pundit put it, ” the FED is...
by Raynovich Rod | Feb 28, 2022 | 2021 Rayno Biopharmaceuticals Portfolio, Healthcare stocks
Update-2 3/2…Broad rally takes all sectors higher. Powell confirms 0.25% rate incr and talks the talk.A bit of rotation to the re-opening trade with industrials, ag and rails moving up. Core large caps up:ABBV, GILD, JNJ, REGN,VRTX. Med-tech up:...
by Raynovich Rod | Feb 14, 2022 | 2021 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1 2/25 Broad Rally Includes Materials XLB, Financials XLF and Healthcare XLV. Dow leads up 2.44%.Investors seek safety of large caps with dividends. XLV up 3% to $130.93. IBB up 1% XBI up 0.43%, QQQ up 1.3%. Large cap leaders: UNH and PFE up over 4%, AMGN AZN...
by Raynovich Rod | Feb 8, 2022 | 2021 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Macro
At close 2/11: Another crappy day now with Ukraine Crisis coming to fore. But some large cap biopharmas get green: BMY. GILD, REGN up 3.27%, and PFE. Nibbled on NeuroCrine (NBIX) at $85. Update-3 2/11 12p EST…Small caps fight the headwinds but “hold the...
by Raynovich Rod | Jan 23, 2022 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio
Update-1 AAPL ignited rally? Either by oversold conditions or good earnings by AAPL and MSFT we have lift -off from the bottom. If your speculative biotech stocks did not go up today you may want to dump it. Our mid-cap focus list saw nice gains except for CRSP. ARKG...
